Daval International Limited is a UK-based biotechnology company focused on the development and delivery of novel and distinctive treatments. From its inception in 2000, Daval has had a vision of bringing effective treatments that noticeably improve the quality of life of patients suffering from the most serious debilitating neuro-degenerative, inflammatory and autoimmune diseases to realisation and to offer a choice over and above some of the disease modifying treatments available currently.
Daval’s lead product candidate, AIMSPRO® (Hyperimmune Caprine Sera, HICS) is a proprietary, purified protein multi-peptide conjugate complex being developed as a novel, first-in-class biological treatment for a number of immune diseases where regulation and stabilisation of the immune system is required. AIMSPRO® has a unique mechanism of action that supports its broad potential application in a wide range of neuro-degenerative, inflammatory and autoimmune diseases.
Daval has focused its development plans in three indications to date: Scleroderma, Secondary Progressive Multiple Sclerosis (SPMS) and Amyotrophic Lateral Sclerosis (ALS). Daval has completed Phase IIa proof of concept studies for Scleroderma and SPMS at London’s Royal Free Hospital, and is also conducting open-label studies for the treatment of patients with ALS and SPMS. Other disease indications are under active investigation.
AIMSPRO® has been granted a Specials License by the UK's MHRA and is available in Australia under Categories A and B of the TGA's Special Access Scheme. AIMSPRO® has also been granted Orphan Drug Designation status in the United States of America and in Australia.